Answers are grounded in this paper and cite their sources.
Background Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Metabolic reprogramming play critical roles in HCC progression and treatment response, but effective therapeutic targets and targeted therapies remain urgently needed. Methods This study performed integrated bioinformatics analysis, cellular functional assays, virtual screening, peptidomics profiling, and in vivo xenograft models to investigate the role of aminopeptidase-like 1 (NPEPL1) in HCC and evaluate its small-molecule inhibitor C301-9181. Results NPEPL1 was markedly overexpressed in HCC, and its upregulation significantly correlated with poor prognosis. NPEPL1 knockdown suppressed HCC cell proliferation, migration, and invasion while promoting apoptosis, whereas overexpression yielded opposite effects, supporting the oncogenic role of NPEPL1 in HCC. Mechanistically, serum response factor (SRF) directly binds to and transcriptionally activates the NPEPL1 promoter via three binding sites. Peptidomics revealed that NPEPL1 functions as a hydrophobic/aliphatic aminopeptidase, preferentially cleaving N-terminal hydrophobic residues, thereby remodeling translation and mitochondrial metabolism and contributing to HCC progression. Through virtual screening, we identified C301-9181 as a novel small-molecule inhibitor of NPEPL1 that directly binds NPEPL1 with micromolar affinity (K D = 2.77 µM), suppresses NPEPL1 expression and aminopeptidase activity, and exhibits anti-HCC efficacy in vitro and in vivo with an acceptable biosafety profile. In vitro, C301-9181 exhibited antiproliferative activity comparable to sorafenib and superior to lenvatinib, with greater selectivity than sorafenib, and enhanced the anti-HCC effects of both existing HCC therapeutic drugs. Conclusions Our work supports NPEPL1 as a novel prognostic biomarker and therapeutic target in HCC, and presented C301-9181 as a novel NPEPL1 inhibitor C301-9181 with warranting further preclinical evaluation, highlighting a potential precision therapeutic strategy for HCC.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: